7 results about "Tedizolid" patented technology

The invention relates to tedizolid gel and a preparation method thereof. The tedizolid gel is prepared from the following raw materials and auxiliary materials: an active component, a gel matrix, an alcohol solvent, a bacteriostatic agent, a pH regulator and water, the active component is tedizolid or ester thereof, or pharmaceutically acceptable salt thereof; the gel matrix is carbomer. The tedizolid gel can increase the local tissue free drug concentration of the skin of the bacterial infection part of an organism through transdermal absorption, so that the bacteriostatic activity of the tedizolid gel is better played, the treatment effect on local acute bacterial skin and skin soft tissue infection is improved, and the adverse reaction is reduced.

The application provides a tediroxine injection as well as a preparation method and application thereof, and belongs to the technical field of animal medicine. The tediroxine injection provided by the application comprises tediroxine, poloxamer, polyhydric alcohol, a pH regulator and water, the concentration of the tediroxine in the tediroxine injection is 0.04-0.18 g / mL, and the mass ratio of the tediroxine, the poloxamer and the polyhydric alcohol is 4-18:0.4-1.8:50. The polyhydric alcohol and the poloxamer are compounded in the application, the slow release of the tediroxine is realized, the further enrichment of the tediroxine in the respiratory tract is realized, the stimulation problem caused by the tediroxine is solved, the curative effect is improved, and the drug dosage can be reduced.

The application provides a preparation method of a phosphoric acid detazolamide intermediate and phosphoric acid detazolamide, which has mild reaction conditions, avoids extremely low reaction temperature (below -70 DEG C), avoids the use of toxic tin reagents and extremely flammable butyl lithium, has low cost, can significantly improve yield and purity, and has the phosphoric acid detazolamide prepared by the method, the purity of which is not less than 99.6%, and the quality is stable after accelerated storage for 6 months.

This invention relates to a hybridoma cell line that secretes linezolid monoclonal antibodies and its applications, belonging to the field of immunoassay technology. Through multiple screening processes, this invention has obtained a hybridoma cell line that secretes linezolid monoclonal antibodies. The linezolid monoclonal antibody secreted by this hybridoma cell line exhibits excellent affinity and sensitivity to linezolid, with a high IC50 value for linezolid. 50 The concentration reaches 50 ng / mL, and there is no cross-reactivity with linezolid structural analogs, such as terdizolid and contezolid. Therefore, the monoclonal antibody of this invention can be used to prepare immunoassay products for linezolid, providing an efficient detection method and means for the detection of linezolid residues in food.

The efficient preparation method of a tedizolid intermediate includes the following steps: 1) subjecting 2-fluoro-4-substituted phenylacetic acid to a reaction with a Vilsmeier reagent, and adding a resulting reaction solution to an MX aqueous solution for quenching to obtain an intermediate shown in formula (II); and 2) subjecting the intermediate shown in formula (II) obtained in step 1) and 1-(2-methyl-2H-tetrazol-5-yl)ethanone to one-pot synthesis in the presence of an alkali and an ammonia source to obtain the intermediate shown in formula (I). In this method, a pyridine ring of the key intermediate shown in formula (I) is obtained through a ring-closing reaction of the 1-(2-methyl-2H-tetrazol-5-yl)ethanone and a Vinamidinium salt, and a key methyltetrazolyl group is introduced into the structure, which successfully avoids the use of highly-toxic sodium cyanide and sodium azide, the use of expensive palladium catalyst, and the use of methylation with low selectivity.

The invention discloses an efficient catalysis process for synthesis of tildipirosin, and relates to the technical field of synthesis of tildipirosin. The method comprises the following steps: dissolving tylosin phosphate in toluene, discharging the solution into a reaction tube by a liquid pump, and discharging a sodium borohydride / methanol system into the reaction tube from an upper branch tube of the reaction tube to obtain a tylosin compound A; discharging the tylosin compound A into a first reaction tank system at a fixed flow rate, and discharging the tylosin compound A into a first reaction tank one by one to obtain a tylosin compound B; discharging the tylosin compound B into a second reaction tank system at a fixed flow rate, and discharging the tylosin compound B into a second reaction tank one by one to obtain a tylosin compound C; and adding the tylosin compound C into an amination tank, adding piperidine, potassium carbonate and acetonitrile to obtain a tildipirosin crude product, and recrystallizing and refining the tildipirosin crude product. According to the method, the aldehyde group at the C20 site of tylosin is oxidized into the hydroxyl group, so that only one amination reaction is carried out later, and the problems of more byproducts, difficulty in separation, difficulty in reaction controllability and the like in the conventional two amination reactions are solved.

The invention relates to a hybridoma cell strain capable of secreting a tildipirosin monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain provided by the invention has good sensitivity and specificity to the tildipirosin, wherein the IC50 value to the tildipirosin is 20 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of tildipirosin, such as erythromycin, streptomycin, azithromycin and spiramycin, and has good specificity, so that low-concentration tildipirosin can be accurately detected.